Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z8LE
|
|||
| Former ID |
DNC008416
|
|||
| Drug Name |
17-dehydroxyriccardin C
|
|||
| Synonyms |
17-dehydroxyriccardin C; Riccardin C derivative, 20b; CHEMBL409652; BDBM23849; 2',4-[Ethylene-1,4-phenylene-oxy-(6-hydroxy-1,3-phenylene)-ethylene]-1,1'-biphenyl-2-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H24O3
|
|||
| Canonical SMILES |
C1CC2=CC=CC=C2C3=C(C=C(CCC4=CC(=C(C=C4)O)OC5=CC=C1C=C5)C=C3)O
|
|||
| InChI |
1S/C28H24O3/c29-26-16-11-21-6-5-20-10-15-25(27(30)17-20)24-4-2-1-3-22(24)12-7-19-8-13-23(14-9-19)31-28(26)18-21/h1-4,8-11,13-18,29-30H,5-7,12H2
|
|||
| InChIKey |
OAEVJFPPXJHCKV-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxysterols receptor LXR-alpha (NR1H3) | Target Info | Inhibitor | [1] |
| Oxysterols receptor LXR-beta (NR1H2) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | PPAR signaling pathway | |||
| Non-alcoholic fatty liver disease (NAFLD) | ||||
| Hepatitis C | ||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| Nuclear Receptors Meta-Pathway | ||||
| PPAR Alpha Pathway | ||||
| Liver X Receptor Pathway | ||||
| Adipogenesis | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| Nuclear Receptors | ||||
| SREBP signalling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.